JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Search

AcelRx Pharmaceuticals Inc

Slēgts

0

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+532.91% upside

AcelRx Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. febr. 00:00 UTC

Karstas akcijas

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

2026. g. 4. febr. 22:55 UTC

Peļņas

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

2026. g. 4. febr. 21:44 UTC

Peļņas

Arm Holdings 3Q Profit Falls Despite Revenue Growth

2026. g. 4. febr. 21:39 UTC

Peļņas

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

2026. g. 5. febr. 00:00 UTC

Peļņas

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

2026. g. 5. febr. 00:00 UTC

Peļņas

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

2026. g. 4. febr. 23:46 UTC

Tirgus saruna

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

2026. g. 4. febr. 23:45 UTC

Peļņas

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

2026. g. 4. febr. 23:32 UTC

Tirgus saruna

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

2026. g. 4. febr. 22:59 UTC

Iegādes, apvienošanās, pārņemšana

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

2026. g. 4. febr. 22:30 UTC

Peļņas

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

2026. g. 4. febr. 22:30 UTC

Peļņas

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

2026. g. 4. febr. 22:21 UTC

Peļņas

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026. g. 4. febr. 22:17 UTC

Tirgus saruna

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

2026. g. 4. febr. 22:15 UTC

Tirgus saruna

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

2026. g. 4. febr. 22:00 UTC

Tirgus saruna

ESG Roundup: Market Talk

2026. g. 4. febr. 21:53 UTC

Peļņas

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

2026. g. 4. febr. 21:51 UTC

Peļņas

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026. g. 4. febr. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 4. febr. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 4. febr. 21:50 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2026. g. 4. febr. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 4. febr. 21:45 UTC

Peļņas

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

2026. g. 4. febr. 21:44 UTC

Peļņas

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

2026. g. 4. febr. 21:43 UTC

Peļņas

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

2026. g. 4. febr. 21:41 UTC

Peļņas

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

2026. g. 4. febr. 21:36 UTC

Tirgus saruna

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

2026. g. 4. febr. 21:30 UTC

Peļņas

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026. g. 4. febr. 21:30 UTC

Peļņas

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026. g. 4. febr. 21:30 UTC

Peļņas

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Salīdzinājums

Cenas izmaiņa

AcelRx Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

532.91% augšup

Prognoze 12 mēnešiem

Vidējais 5 USD  532.91%

Augstākais 5 USD

Zemākais 5 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AcelRx Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

$

help-icon Live chat